In vitro release behavior of dextran-methacrylate hydrogels using doxorubicin and other model compounds

Journal of Biomaterials Applications

Volumn 15, Issue 1, 2000, Pages 23-46

  Kim, Sin Hee ^a   Chu, Chih Chang ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDITY; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; IONIZATION; MOLECULAR WEIGHT; PH EFFECTS;

DEGREE OF SUBSTITUTION; DEXTRAN METHACRYLATE HYDROGELS; DOXORUBICIN;

HYDROGELS;

ACID; ALIZARIN RED S; ALKALI; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BIOMATERIAL; COLORING AGENT; CROSS LINKING REAGENT; DEXTRAN; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; FLUORESCENT DYE; METHACRYLIC ACID DERIVATIVE; POLYMER;

ARTICLE; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG DELIVERY SYSTEM; HUMAN; HYDROGEL; MATERIALS TESTING; MOLECULAR WEIGHT; PH; TIME;

ACIDS; ALKALIES; ANTHRAQUINONES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; COLORING AGENTS; CROSS-LINKING REAGENTS; DELAYED-ACTION PREPARATIONS; DEXTRANS; DIFFUSION; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HUMANS; HYDROGELS; HYDROGEN-ION CONCENTRATION; MATERIALS TESTING; METHACRYLATES; MOLECULAR WEIGHT; POLYMERS; TIME FACTORS;

EID: 0034214871     PISSN: 08853282     EISSN: None     Source Type: Journal    
DOI: 10.1106/ML30-FMLG-1HRU-7C4B     Document Type: Article

References (39)

1. Arcamone, F. 1981. Doxorubicin, Anticancer Antibiotics, New York: Academic Press, 16-47, 93-125.
2. Remers, W. A. 1979. The Chemistry of Antitumor Antibiotics, New York: John Wiley & Sons, 108-127.
3. Jurczak, J. and Golebiowski, A. 1993. Antibiotics and Antiviral Compounds, Weinheim: VCH, 352-356.
4. Arcamone, F. 1980. Anticancer Agents Based on Natural Product Models, New York: Academic Press, 1-41.
5. Barabas, K., Sizensky, J. A. and Faulk, W. P. 1992. "Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA," J. Biol. Chem., 267:9437-9442.
6. Arrington, K. A., Legendre, A. M., Tabeling, G. S. and Frazier, D. L. 1994. "Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs," Am. J. Vet. Res., 55:1587-1592.
7. Boucek, R. J., Olson, R. D., Brenner, D. E., Ogunbunmi, E. M., Inui, M. and Fleischer, S. 1987. "The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps," J. Biol. Chem., 262:15851-15856.
8. Matherne, C. M., Satterfield, W. C., Gasparini, A., Tonetti, M., Astroff, A. B., Schmidt, R. D., Rowe, L. D. and DeLoach, J. R. 1994. "Clinical efficacy and toxicity of doxorubicin encapsulated in glutaraldehyde-treated erythrocytes administered to dogs with lymphosarcoma," Am. J. Vet. Res., 55:847-853.
9. Tonetti, M., Astroff, A. B., Satterfield, W., Flora, A. D., Benatti, U. and DeLoach, J. R. 1990. "Pharmacokinetic properties of doxorubicin encapsulated in glutaraldehyde-treated canine erythrocytes," Am. J. Vet. Res., 52:1630-1635.
10. Arap, W., Pasqualini, R. and Ruoslahti, E. 1998. "Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model," Science, 279:377-379.
11. Gupta, P. K. and Hung, C. T. 1990. "Comparative disposition of adriamycin delivered via magnetic albumin microspheres in presence and absence of magnetic field in rats," Life Sciences, 46:471-479.
12. Ferruti, P. 1979. "Synthesis and exchange reactions of biodegradable drug-binding matrices," Makromol. Chem., 180:375-382.
13. Spinney, L. 1994. "Sugar-coated crystals could take gene therapy into brain," Science, 16.
14. Dan, W. and Saltzman, W. M. 1992. "Dextran retention in the rat brain following release from a polymer implant," Biotechnol. Prog., 8:527-532.
15. Sidebotham, R. L. 1974. Advances in Carbohydrate Chemistry and Biochemistry, New York: Academic Press, 371-383.
16. Park, K., Shalaby, W. S. W. and Park, H. 1993. Biodegradable Hydrogels for Drug Delivery, Lancaster, PA: Technomic Publishing Company, Inc., 85-87.
17. Sery, T. W. and Hehre, E. J. 1956. "Degradation of dextrans by enzymes of intestinal bacteria," J. Bacteriology, 71:373-380.
18. Dijk-Wolthuis, W. N. E. v., Hoogeboom, J. A. M., Steenbergen, M. J. v., Tsang, S. K. Y. and Hennink, W. E. 1997. "Degradation and release behavior of dextran-based hydrogels," Macromolecules, 30:4639-4645.
19. Sawhney, A. S., Pathak, C. P. and Hubbell, J. A. 1993. "Bioerodible hydrogels based on photopolymerized poly(ethylene glycol)-co-poly-(α-hydroxy acid) diacrylate macromers,α Macromolecules, 26:581-587.
20. Vyavahare, N. and Kohn, J. 1994. αPhotocrosslinked hydrogels based on copolymers of poly(ethylene glycol) and lysine," J. Poly. Sci., Part A: Polym. Chem., 32:1271-1281.
21. Graham, N. B. and McNell, M. E. 1984. "Hydrogels for controlled drug delivery," Biomaterials, 5:27-36.
22. Hennink, W. E., Talsma, H., Borchert, J. C. H., Smedt, S. C. D. and Demeester, J. 1996. "Controlled release of proteins from dextran hydrogels," J. Control. Release, 39:47-55.
23. Franssen, O., Vos, O. P. and Hennink, W. E. 1997. "Delayed release of a model protein from enzymatically-degrading dextran hydrogels," J. Control. Release, 44:237-245.
24. Andreopoulos, F. M., Deible, C. R., Stauffer, M. T., Weber, S. G., Wagner, W. A., Beckman, E. J. and Russell, A. J. 1996. "Photoscissable hydrogel synthesis via rapid photopolymerization of novel PEG-based polymers in the ab sence of photoinitiators," J. Am. Chem. Soc., 118:6235-6240.
25. Elisseeff, J., Anseth, K., Langer, R. and Hrkach, J. 1997. "Synthesis and characterization of photocrosslinked polymers based on poly(L-lactic acid-co-L aspartic acid)," Macromolecules, 30:2182-2184.
26. Kim, S.-H., Won, C.-Y. and Chu, C.-C. In Press. "Synthesis and characterization of dextran-maleic acid based hydrogel," J. Biomed. Mater. Res.
27. Kim, S.-H. and Chu, C.-C. Pending. "Synthesis and characterization of dextran-methacrylate hydrogel and its structural study by SEM," J. Biomed. Mater. Res.
28. Baker, R. 1987. Controlled Release of Biologically Active Agents, New York: John Wiley & Sons, 1-105.
29. Lillie, R. D. 1977. H. J. Conn's Biological Stains, Baltimore: The Williams & Wilkins Company, 432-433.
30. Williams Jr., T. W. 1941. "Alizarin Red S and Toluidine Blue for differentiating adult or embryonic bone and cartilage," Stain Technology, 16:23-25.
31. Sinsheimer, J. E., Jagodic, V. and Burckhalter, J. H. 1974. "Fluorescein isothiocyanates: Improved synthesis and purity spectral studies," Anal. Biochem., 57:227-231.
32. Aoyagi, T., Nakamura, A., Ikeda, H., Ikeda, T., Mihara, H. and Ueno, A. 1997. "Alizarin yellow-modified β-cyclodextrin as a guest-responsive absorption change sensor," Anal. Chem., 69:659-663.
33. Benthem, M. H. V. and Gillispie, G. D. 1984. "Intramolecular hydrogen bonding. 4. Dual fluorescence and excited-state proton transfer in 1,5-dihydroxyanthraquinone," J. Phys. Chem., 88:2654-2960.
34. Helfferich, F. 1962. Ion Exchange, New York: McGraw-Hill Book Company, Inc., 95-125.
35. Sturgeon, R. J. and Schulman, S. G. 1977. "Electronic absorption spectra and protolytic equilibria of doxorubicin: Direct spectrophotometric determination of microconstants," J. Pharm. Sci., 66:958-961.
36. Barthelemy-Clavey, V., Maurizot, J.-C., Dimicoli, J.-L. and Sicard, P. 1974. "Self-association of daunorubicin," FEBS Letters, 46:5-10.
37. Eksborg, S. 1978. "Extraction of daunorubicin and doxorubicin and their hydroxyl metabolites: self-association in aqueous solution," J. Pharm. Sci., 67:782-785.
38. Edwards, D. A., Hanes, J., Caponetti, G., Hrkach, J., Ben-Jebria, A., Eskew, M. L., Mintzes, J., Deaver, D., Lotan, N. and Langer, R. 1997. "Large porous particles for pulmonary drug delivery," Science, 276:1868-1871.
39. Jones, C., Burton, M. A. and Gray, B. N. 1989. "Albumin microspheres as vehicles for the sustained and controlled release of doxorubicin," J. Pharm. Pharmacol., 41:813-816.